KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab.

Sci Rep · 2023 · PMC10687227 · PMID 38030703

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

There was an overall trend for higher response rates (complete plus partial responses) in high KRAS4A and KRAS4B cmRNA expression groups.

also in 2,475 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.